The University of Bayreuth's Biomaterials research group has, for the first time, successfully applied the CRISPR-Cas9 ...

“We have demonstrated, for the first time worldwide, that CRISPR-Cas9 can be used to incorporate a desired sequence into ...

Adoptive cell therapy based on ex-vivo expanded tumor-infiltrating lymphocytes (TILs) has historically been most effective in ...

CRISPR Therapeutics benefits from Casgevy’s approval and a deep pipeline, despite early rollout hurdles and cost challenges.

Targeting the intracellular immune checkpoint CISH with CRISPR-Cas9-edited tumor-infiltrating lymphocytes ... might be ...

Beam Therapeutics and Verve Therapeutics have each built their lead candidates on a technique billed as a safer alternative ...

The CRISPR/Cas9 gene-editing technique has shown promise in fighting advanced colorectal cancer, according to results of the ...

A first-in-human clinical trial tests a CRISPR/Cas9 gene-editing technique to help the immune system fight advanced gastrointestinal (GI) cancers.

"Our study is a first step in dramatically expanding our repertoire of effective and safe CRISPR-Cas9 enzymes. In our manuscript, we demonstrate the utility of these PAMmla-predicted enzymes to ...

“Gene editing technologies like CRISPR/Cas9 offer exciting possibilities ... to accelerate bold and impactful research,” explained Katherine Forsey, PhD, Chief Research Officer at CMTA.

In a new study published in Nature titled, “Custom CRISPR-Cas9 PAM variants via scalable engineering and machine learning,” researchers from Massachusetts General Hospital (MGH) and Harvard ...